Roquette in the news

Roquette has partnered with Axéréal and Oxyane to advance regenerative agriculture and secure sustainably sourced raw materials, supporting its 2030 objectives.

Roquette expands its regenerative agriculture initiatives through new partnerships with Axereal and Oxyane to source sustainably farmed raw materials.

Roquette experienced substantial growth in the first half of 2026, driven by new product lines in pharma and health, strong performance in key markets, and effective cost management.

Roquette achieved progress in the first half of 2026 due to increased sales in pharmaceutical applications and strong results in protein and fiber, supported by a 600 million euro bond issuance and the "Shift & Lead" strategic program.

Roquette will showcase its pharmaceutical excipients, drug delivery solutions, and biopharmaceutical expertise at CPHI Milan 2026.

Roquette will present its comprehensive portfolio of pharmaceutical excipients and drug delivery solutions at CPHI Milan 2026.

Roquette will present its pharmaceutical excipients, drug delivery solutions, and biopharmaceutical innovations at CPHI Milan 2026, including a new hard capsule product.

Roquette will showcase its pharmaceutical excipients and drug delivery solutions, including new Qualicaps additions, at CPHI Milan 2026 to address complex formulation challenges for patient-centric solutions.

Roquette will present its comprehensive pharmaceutical excipients and drug delivery solutions at CPHI Milan 2026.

Roquette will exhibit its comprehensive range of pharmaceutical excipients and drug delivery solutions at CPHI Milan 2026, showcasing new Qualicaps additions and engaging visitors with interactive displays.

Roquette will showcase its end-to-end pharma solutions, including excipients and drug delivery systems, at CPHI Milan 2026 to highlight patient-centric formulations and biopharma innovation.

Roquette and Seaweed & Co. are innovating alternative protein ingredients to cater to flexitarians and address nutritional gaps in plant-based diets, focusing on taste, texture, and functionality.

Roquette reported a 9% increase in turnover and an 18% rise in Current EBITDA for H1 2026, driven by strong growth in pharmaceutical ingredients and plant-based nutrition, alongside the initial success of its "Shift & Lead" strategic plan.

Roquette reported strong first-half 2026 financial results with significant turnover and EBITDA growth, fueled by its strategic transformation program and robust performance in key product segments.

Roquette achieved 9% revenue growth and an 18% increase in EBITDA in H1 2026, driven by its strategic transformation program, new product lines, and cost discipline, despite challenging market conditions.

Roquette achieved a 9% increase in H1 2026 turnover and an 18% rise in Current EBITDA, driven by pharmaceutical and healthcare segments.

Roquette posted strong H1 2026 financial results with significant turnover and EBITDA growth, fueled by its strategic transformation and expansion into high-value pharmaceutical and nutritional products.

Roquette reported strong financial results in the first half of 2026, with significant revenue and EBITDA growth, driven by pharmaceutical and health solutions, strategic portfolio expansion, and cost management.

Negotiations over job cuts at Roquette in Lestrem are deadlocked, leading the CFDT union to consider further strikes.